8-K: AtriCure Announces Strong First Quarter 2024 Results with 16.4% Revenue Growth

AtriCure reported a 16.4% year-over-year increase in worldwide revenue for the first quarter of 2024, reaching $108.9 million.

Summary

• AtriCure's worldwide revenue for the first quarter of 2024 reached $108.9 million, a 16.4% increase compared to the same period in 2023.
• On a constant currency basis, revenue grew by 16.3%.
• U.S. revenue increased by 15.4% to $90.2 million, driven by sales across key product lines.
• International revenue saw a 21.5% increase to $18.6 million, with growth across all franchises and geographic regions.
• Gross profit for the quarter was $81.3 million, with a gross margin of 74.7%.
• The company reported a loss from operations of $10.9 million, compared to a $5.8 million loss in the first quarter of 2023, impacted by a $4.0 million gain from a legal settlement in 2023.
• Basic and diluted net loss per share was $0.28, compared to $0.14 in the first quarter of 2023.
• Adjusted EBITDA for the quarter was $2.8 million, an increase of $0.9 million over the first quarter of 2023.
• Adjusted loss per share was $0.25, compared to $0.23 for the first quarter of 2023.
• Full year 2024 revenue is projected to be between $459 million and $466 million, representing a 15% to 17% growth over 2023.
• The company expects full year 2024 Adjusted EBITDA to be between $26 million and $29 million, a 34% to 49% increase over 2023.
• Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.82.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improved adjusted EBITDA. While there are losses, the overall tone is optimistic due to the growth trajectory and future guidance.

Positives

• The company experienced strong revenue growth across all franchises and geographic regions.
• Gross margin improved, indicating better product and geographic mix.
• Adjusted EBITDA showed a significant increase compared to the same quarter last year.
• The company is projecting strong revenue and adjusted EBITDA growth for the full year 2024.
• The company is focused on expanding the reach of its solutions for patients with advanced Afib, managing the LAA, and reducing post-operative pain.

Negatives

• The company reported a loss from operations of $10.9 million, which is higher than the $5.8 million loss in the first quarter of 2023.
• Basic and diluted net loss per share was $0.28, compared to $0.14 in the first quarter of 2023.
• There was pressure in minimally invasive appendage management products, primarily from a decline in LARIAT system sales.
• Adjusted loss per share was $0.25, compared to $0.23 for the first quarter of 2023.

Risks

• The company's actual results could differ materially from forward-looking statements due to various uncertainties.
• The company faces risks related to market adoption of its products and competition.
• Changes in foreign currency exchange rates can impact revenue.
• The company's financial performance is subject to various economic and market conditions.

Future Outlook

Full year 2024 revenue is projected to be approximately $459 million to $466 million, with adjusted EBITDA between $26 million and $29 million. Adjusted loss per share is expected to be in the range of $0.74 to $0.82.

Management Comments

• Michael Carrel, President and Chief Executive Officer at AtriCure, stated that the company had a strong start to 2024, with growth across all franchises worldwide.
• Management is focused on expanding the reach of their solutions for patients with advanced Afib, managing the LAA, and reducing post-operative pain.
• Management looks forward to advancing clinical research initiatives and launching several new products this year.

Industry Context

AtriCure operates in the medical device industry, specifically focusing on treatments for atrial fibrillation and related conditions. The company's growth reflects the increasing prevalence of Afib and the demand for effective treatment options. The company competes with other medical device companies in the cardiac surgery and electrophysiology space.

Comparison to Industry Standards

• AtriCure's 16.4% revenue growth is strong compared to the overall medical device industry, which typically sees single-digit growth.
• Companies like Medtronic and Abbott, which also operate in the cardiac device space, have reported varying growth rates, but AtriCure's growth is notable.
• The company's focus on minimally invasive procedures and innovative technologies positions it well in the market.
• The gross margin of 74.7% is competitive within the medical device industry, indicating efficient operations and pricing strategies.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and positive outlook favorably.
• Employees may be motivated by the company's growth and success.
• Customers (physicians and hospitals) will benefit from the company's innovative technologies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will continue to focus on expanding the reach of its solutions for patients with advanced Afib.
• The company will advance its clinical research initiatives.
• The company plans to launch several new products this year.
• The company will host a conference call to discuss the financial results.

Key Dates

Keywords

AtriCure, atrial fibrillation, Afib, LAA management, post-operative pain management, surgical treatments, revenue growth, EBITDA, medical devices, cardiac surgery